Morgan Stanley expects Novo Nordisk Alzheimer trial to fail as it slashes rating

Morgan Stanley downgraded Novo Nordisk to underweight from equal weight and cut its price target to $47 from $59, citing a 75% probability that the company's semaglutide Alzheimer's trial will fail to achieve statistical significance, which is expected to trigger a high single-digit percentage share price decline. The firm also highlighted concerns over declining Ozempic prescription growth, increasing competition from Eli Lilly's Mounjaro, anticipated Medicare Part D price cuts for semaglutide, and a lack of differentiation for Novo Nordisk's next-gen weight-loss drug CagriSema. Novo Nordisk shares slipped 3% in premarket trading following the report.

Analysis

Morgan Stanley's downgrade of Novo Nordisk to "underweight" with a significant price target cut to $47 from $59 signals a confluence of material risks. The primary catalyst is the firm's expectation of a 75% probability that the pivotal semaglutide Alzheimer's trial will fail to show statistical significance, an event projected to trigger a high single-digit percentage share price decline. This bearish outlook is compounded by deteriorating fundamentals and competitive pressures; weekly prescription data for Ozempic is reportedly declining while competitor Eli Lilly’s Mounjaro demonstrates linear growth. Furthermore, Morgan Stanley anticipates two future headwinds: a severe 50% price cut for semaglutide under Medicare Part D and a potential lack of differentiation for Novo's next-generation drug, CagriSema, in its head-to-head trial against Lilly's Zepbound. The immediate 3% premarket share price drop to $53.80 indicates that investors are pricing in these mounting concerns.

Key Decisions for Investors

• Given the multiple near-term negative catalysts outlined by Morgan Stanley, investors with long positions in Novo Nordisk should re-evaluate their exposure and consider hedging strategies ahead of the Alzheimer's trial results.
• The contrasting growth trajectories between Ozempic and Mounjaro suggest a potential pair trade opportunity, favoring Eli Lilly over Novo Nordisk, to capitalize on the shifting competitive dynamics in the weight-loss drug market.
• The upcoming Alzheimer's trial data represents a significant binary event; investors should monitor the results closely as a failure is the core of the bearish thesis, while an unexpected success would materially alter the stock's outlook.